KX-01-191 is primarily investigated for its potential in cancer therapy, particularly as an inhibitor of specific cellular pathways involved in tumor growth and proliferation. It has shown promise in targeting cancer cells while sparing normal cells, making it a candidate for selective anti-cancer treatments. Research focuses on its ability to disrupt key signaling mechanisms that drive cancer progression, potentially enhancing the effectiveness of existing therapies. Additionally, it is being studied for its role in overcoming drug resistance in certain cancers, offering a new avenue for treatment strategies. Preclinical studies suggest its application in various cancer types, including solid tumors and hematologic malignancies, though further clinical trials are needed to confirm its efficacy and safety.